Anti-mouse CD25 Monoclonal Antibody | PA007156.m2caf

Name: Anti-mouse CD25 Antibody (Clone:PC61, PC61.5 or PC61.5.3) | Ushelf
Brand: Syd Labs
SKU: PA007156.m2caf
Price: 295-2950 USD
Availability: InStock
Rating: 5 (1 reviews)

$295.00 – $2,950.00

In Vivo Grade Recombinant Afucosylated Anti-mouse CD25 Mouse IgG2c Kappa Monoclonal Antibody. Recombinant anti-mouse CD25 mouse IgG2c monoclonal antibodies (clone: PC61, PC61.5 or PC61.5.3) produced from CHO or engineered CHO cell lines good for in vitro and in vivo studies. The afucosylated antibody may behave better in in vivo regulatory T cell depletion.

Details & Specifications
References

Catalog No.	PA007156.m2caf
Product Name	In vivo Grade Recombinant Afucosylated Anti-mouse CD25 Monoclonal Antibody (Clone PC61.5.3), Mouse IgG2c Kappa
Supplier Name	Syd Labs, Inc.
Brand Name	Syd Labs
Synonyms	IL-2Rα, Ly-43, p55, Tac
Summary	The In vivo Grade Recombinant Afucosylated Anti-mouse CD25 Mouse IgG2c Kappa Monoclonal Antibody was produced in CHO cells.
Clone	PC61, PC61.5 or PC61.5.3
Isotype	mouse IgG2c, kappa
Applications	immunoprecipitation (IP), immunohistochemistry (IHC), Flow Cytometry (FC), and various functional assays, such as in vivo depletion of CD25+CD4+ Treg cells, in vitro blocking of IL-2 binding to low- and high-affinity receptors, and growth inhibition of IL-2-dependent T-cell lines.
Immunogen	IL-2-dependent cytolytic mouse T-cell clone B6.1.
Form Of Antibody	0.2 μM filtered solution of 1x PBS.
Endotoxin	Less than 1 EU/mg of protein as determined by LAL method.
Purity	>95% by SDS-PAGE under reducing conditions.
Shipping	The In Vivo Grade Recombinant Afucosylated Anti-mouse CD25 Mouse IgG2c Kappa Monoclonal Antibody are shipped with ice pack. Upon receipt, store it immediately at the temperature recommended below.
Stability & Storage	Use a manual defrost freezer and avoid repeated freeze-thaw cycles. 1 month from date of receipt, 2 to 8°C as supplied. 3 months from date of receipt, -20°C to -70°C as supplied.
Note	Recombinant anti-mouse CD25 mouse IgG2c monoclonal antibodies (clone: PC61, PC61.5 or PC61.5.3) produced from CHO or engineered CHO cell lines good for in vitro and in vivo studies. The afucosylated antibody may behave better in in vivo regulatory T cell depletion.
Order Offline	Phone: 1-617-401-8149 Fax: 1-617-606-5022 Email: message@sydlabs.com Or leave a message with a formal purchase order (PO) Or credit card.

Description

PA007156.m2caf: Recombinant Anti-mouse CD25 Monoclonal Antibody (Clone: PC61, PC61.5 or PC61.5.3), Mouse IgG2c Kappa, In vivo Grade

Background

The in vivo grade recombinant anti-mouse CD25 monoclonal antibodies are based on the rat monoclonal antibody anti-CD25 (mouse) with the clone number of PC61, PC61.5 or PC61.5.3. The rat IgG1 lamda monoclonal antibody has been validated and reported for use in immunoprecipitation (IP), immunohistochemistry (IHC), Flow Cytometry (FC), and various functional assays, such as in vivo depletion of CD25+CD4+ Treg cells, in vitro blocking of IL-2 binding to low- and high-affinity receptors, and growth inhibition of IL-2-dependent T-cell lines. Expression of CD25, together with CD4 and FOXP3, is considered a phenotypic signature for Treg cells. In vivo depletion of mouse CD25(+)CD4(+)FoxP3(+) Treg cells using the rat PC61 monoclonal antibody is widely used to characterize the Treg function. The PC61 monoclonal antibody specifically binds to an epitope of CD25 which is distinct from the IL-2 binding site and from those recognized by the 3C7 and 7D4 monoclonal antibodies. By doing so, the antibody blocks binding of IL-2 to CD25.
The in vivo grade recombinant anti-mouse CD25 mouse IgG2c kappa monoclonal antibody was produced in CHO cells.

References of Anti-Mouse CD25 Monoclonal Antibody (Clone: PC61.5.3)

1. Two novel human anti-CD25 antibodies with antitumor activity inversely related to their affinity and in vitro activity.
Soler-Cardona, et al.Cancers (Basel). 2021 Nov 16;13(22):5730. doi: 10.3390/cancers13225730. PMID: 34827083; PMCID: PMC8617198
“Targeting CD25 (IL-2Rα) to deplete regulatory T cells (Tregs) is a promising strategy to enhance antitumor immunity. … We generated and evaluated two novel human anti-CD25 monoclonal antibodies with distinct binding characteristics. … Interestingly, our results revealed that the antitumor efficacy in syngeneic models was inversely related to antibody affinity and in vitro neutralizing efficacy.”

2. TRAIL suppresses tumor growth in mice by inducing tumor-infiltrating CD4+CD25+ Treg apoptosis.
Wang, et al.Cell Death Dis. 2024 Apr 19;15(4):276. doi: 10.1038/s41419-024-06652-w. PMID: 38641998; PMCID: PMC11028869
“Tumor-infiltrating CD4+CD25+ regulatory T cells (Tregs) heavily contribute to the immunosuppressive tumor microenvironment. … This study evaluates how the TRAIL pathway impacts the survival and frequency of these regulatory populations in mouse tumor models. … The findings indicate that TRAIL delivery effectively suppresses overall tumor growth by selectively inducing apoptosis in CD4+CD25+ Tregs.”

3. A distinct subpopulation of CD25− T-follicular regulatory cells localizes in the germinal centers.
Wing, et al.Proc Natl Acad Sci U S A. 2017 Aug 1;114(31):E6400-E6409. doi: 10.1073/pnas.1705551114. PMID: 28716922; PMCID: PMC5547636
“T-follicular regulatory (Tfr) cells act to control the magnitude of the germinal center B cell response to maintain self-tolerance. … Here, we identify and characterize a prominent subpopulation of Tfr cells that lack CD25 expression. … These unique CD25− Tfr cells selectively localize inside germinal centers and display potent suppressive functions compared to classical CD25+ populations.”

4. IL-2 can signal via chemokine receptors to promote regulatory T cells’ suppressive function.
Luo, et al.Nat Commun. 2023 Oct 10;14(1):6332. doi: 10.1038/s41467-023-42027-z. PMID: 37816739; PMCID: PMC10564087
“Interleukin-2 (IL-2) is heavily recognized as a core driver of regulatory T cell (Treg) activation and survival via the high-affinity CD25 receptor. … We discovered an alternative mechanism where IL-2 directly interacts with chemokine receptors on T cells. … This alternative signaling axis enhances Treg suppressive activity and migration independently of conventional CD25-mediated signaling pathways.”

5. Mast cells suppress murine GVHD in a mechanism independent of CD4+CD25+ regulatory T cells.
Leveson-Gower, et al.Blood. 2013 Nov 21;122(22):3659-3667. doi: 10.1182/blood-2013-02-484170. PMID: 24092937; PMCID: PMC3837515
“Graft-versus-host disease (GVHD) is a major life-threatening complication associated with allogeneic hematopoietic cell transplantation. … Although CD4+CD25+ regulatory T cells are vital for curbing GVHD severity, other suppressive pathways exist. … Our study shows that donor-derived mast cells significantly ameliorate GVHD symptoms via an independent mechanism that does not require host or donor CD4+CD25+ Tregs.”

For more technical references or data sheets regarding the Recombinant Anti-Mouse CD25 Monoclonal Antibody (Clone: PC61.5.3) formats, please contact our scientific support team at message@sydlabs.com.